Natco slumps on Teva's Copaxone appeal

Tags: Companies
Shares in Natco Pharma falls 13 per cent, heading towards their biggest ever single-day fall after the US Supreme Court on Monday agreed to hear an appeal filed by Teva Pharmaceutical Industries Ltd in a patent fight over top-selling multiple sclerosis drug Copaxone.

The appeal could deter generic manufacturers such as Natco from introducing cheaper versions of Capaxone onto the market as soon as May.

The company continues to believe that Teva's patent on Copaxone is "invalid," the company said in a filing to the exchange.

Natco shares had earlier fallen as much as 18.6 percent.

EDITORIAL OF THE DAY

  • Mergers apart, Sebi must also allow fund houses to offer diverse products

    The Securities and Exchange Board of India’s (Sebi’s) reported push for merger of open-ended mutual fund schemes is a logical step, as there is li

FC NEWSLETTER

Stay informed on our latest news!

TODAY'S COLUMNS

Arun Nigavekar

Can Hefa actually become a reality?

The ministry of human resource development (MHRD) is actively wo­rking ...

Kuruvilla Pandikattu

The India of our dreams

The speech “I have a dr­eam,” that Martin Luther King ...

Shona Adhikari

Head to Tate Modern for a refresher course on Bhupen Khakhar

India’s celebrated artist Bhupen Khakhar’s exhibition, titled You Can’t Please ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture